Context Therapeutics (CNTX) Institutional Ownership $0.60 -0.12 (-16.68%) Closing price 04:00 PM EasternExtended Trading$0.61 +0.01 (+1.82%) As of 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Context Therapeutics (NASDAQ:CNTX)CurrentInstitutional OwnershipPercentage14.03%Number ofInstitutional Buyers(last 12 months)22TotalInstitutional Inflows(last 12 months)$63.11MNumber ofInstitutional Sellers(last 12 months)7TotalInstitutional Outflows(last 12 months)$3.14M Get CNTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Context Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CNTX Institutional Buying and Selling by Quarter Remove Ads Context Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/17/2025Velan Capital Investment Management LP90,000$94K0.1%-93.0%0.120% 2/17/2025Shay Capital LLC50,000$52K0.0%N/A0.067% 2/17/2025MPM Bioimpact LLC14,705,882$15.44M2.2%N/A19.608% 2/17/2025Millennium Management LLC178,718$188K0.0%+24.2%0.238% 2/17/2025Citadel Advisors LLC29,900$31K0.0%N/A0.040% 2/17/2025Allostery Investments LP950,166$998K1.0%N/A1.267% 2/17/2025Ally Bridge Group NY LLC1,576,762$1.66M1.4%-10.3%2.102% 2/14/2025Jane Street Group LLC27,395$29K0.0%N/A0.037% 2/14/2025Northern Trust Corp113,565$119K0.0%-34.2%0.151% 2/14/2025Blue Owl Capital Holdings LP6,357,928$6.68M1.6%+17.5%8.477% Get the Latest News and Ratings for CNTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/13/2025Marshall Wace LLP203,286$213K0.0%N/A0.271% 2/13/2025Affinity Asset Advisors LLC1,015,340$1.07M0.1%-23.1%1.354% 2/13/2025Walleye Capital LLC166,306$175K0.0%+51.7%0.222% 2/13/2025Renaissance Technologies LLC338,435$355K0.0%+412.8%0.451% 2/13/2025ADAR1 Capital Management LLC351,094$369K0.1%-6.1%0.468% 2/12/2025Landscape Capital Management L.L.C.90,000$94K0.0%N/A0.120% 2/12/2025Geode Capital Management LLC628,729$661K0.0%+9.2%0.838% 2/12/2025Franklin Resources Inc.4,003,380$4.20M0.0%+115.9%5.338% 1/17/2025Clear Harbor Asset Management LLC57,804$61K0.0%+60.6%0.077% 11/27/2024Franklin Resources Inc.1,853,988$3.69M0.0%N/A2.472% 11/16/2024Geode Capital Management LLC575,899$1.13M0.0%-6.8%0.768% 11/15/2024Y Intercept Hong Kong Ltd45,635$89K0.0%N/A0.061% 11/15/2024State Street Corp111,907$219K0.0%+21.5%0.149% 11/14/2024Ally Bridge Group NY LLC1,757,524$3.45M1.8%-6.8%2.343% 11/13/2024Great Point Partners LLC6,934,982$13.59M4.0%-6.5%9.247% 8/20/2024Nantahala Capital Management LLC1,935,484$3.88M0.2%N/A2.581% 8/16/2024Driehaus Capital Management LLC2,258,065$4.53M0.0%N/A3.011% 8/15/2024Blue Owl Capital Holdings LP5,161,290$10.35M2.9%N/A6.882% 8/15/2024Affinity Asset Advisors LLC1,619,140$3.25M0.4%+392.4%2.159% 8/14/2024Great Point Partners LLC7,419,355$14.88M2.8%N/A9.893% 8/14/2024Ally Bridge Group NY LLC1,886,232$3.78M2.3%+159.8%2.515% 8/9/2024Renaissance Technologies LLC65,200$131K0.0%+63.4%0.087% 5/29/2024Opaleye Management Inc.1,108,357$1.53M0.3%+13.7%1.478% 2/15/2024Opaleye Management Inc.975,000$1.10M0.3%N/A6.107% 11/15/2023Affinity Asset Advisors LLC328,817$497K0.1%+22.9%2.059% 8/21/2023Affinity Asset Advisors LLC267,574$428K0.1%N/A1.675% 7/21/2023Clear Harbor Asset Management LLC36,000$58K0.0%N/A0.225% 2/16/2023AIGH Capital Management LLC1,143,745$745K0.2%-11.5%7.162% 2/14/2023swisspartners Ltd.180,000$119K0.2%+111.8%1.127% 11/14/2022Worth Venture Partners LLC322,628$358K0.2%+8.4%2.021% Trump’s Final Plan (Ad)Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.Click here for the full story. 11/1/2022swisspartners Ltd.85,000$94K0.1%+101.3%0.532% 8/13/2022Virtu Financial LLC46,445$98K0.0%N/A0.291% 8/12/2022Affinity Asset Advisors LLC883,654$1.87M0.8%+13.6%5.535% 5/4/2022swisspartners Ltd.14,315$4.98M3.5%-66.1%0.090% 2/14/2022Altium Capital Management LP493,531$1.31M0.4%N/A4.501% 2/11/2022QCM Cayman Ltd.14,041$37K0.2%N/A0.128% 2/10/2022AIGH Capital Management LLC762,721$2.03M0.6%N/A6.955% 2/9/2022swisspartners Ltd.42,235$114K0.1%N/A0.385% (Data available from 1/1/2016 forward)Remove Ads CNTX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CNTX shares? During the previous two years, 25 institutional investors and hedge funds held shares of Context Therapeutics. The most heavily invested institutionals were MPM Bioimpact LLC ($15.44M), Great Point Partners LLC ($13.59M), Blue Owl Capital Holdings LP ($6.68M), Driehaus Capital Management LLC ($4.53M), Franklin Resources Inc. ($4.20M), Nantahala Capital Management LLC ($3.88M), and Ally Bridge Group NY LLC ($1.66M).Learn more on CNTX's institutional investors. What percentage of Context Therapeutics stock is owned by institutional investors? 14.03% of Context Therapeutics stock is owned by institutional investors. Learn more on CNTX's institutional investor holdings. Which institutional investors have been buying Context Therapeutics stock? Of the 22 institutional investors that purchased Context Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: MPM Bioimpact LLC ($14.71M), Great Point Partners LLC ($7.42M), Blue Owl Capital Holdings LP ($6.11M), Franklin Resources Inc. ($4.00M), Driehaus Capital Management LLC ($2.26M), Nantahala Capital Management LLC ($1.94M), and Affinity Asset Advisors LLC ($1.62M). How much institutional buying is happening at Context Therapeutics? Institutional investors have bought a total of 42,233,909 shares in the last 24 months. This purchase volume represents approximately $64.79M in transactions. Which Context Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Context Therapeutics stock in the last 24 months: Velan Capital Investment Management LP ($1.20M), Great Point Partners LLC ($484.37K), Ally Bridge Group NY LLC ($309.47K), Affinity Asset Advisors LLC ($305.81K), Northern Trust Corp ($58.95K), Geode Capital Management LLC ($42.28K), and ADAR1 Capital Management LLC ($22.74K). How much institutional selling is happening at Context Therapeutics? Institutional investors have sold a total of 2,423,941 shares in the last 24 months. This volume of shares sold represents approximately $3.14M in transactions. Related Companies DSGN Major Shareholders HUMA Major Shareholders ANNX Major Shareholders CRDF Major Shareholders INMB Major Shareholders OCGN Major Shareholders CRVS Major Shareholders ELDN Major Shareholders FHTX Major Shareholders INBX Major Shareholders This page (NASDAQ:CNTX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
